In 2015, John C. Lechleiter earned $13.05M in total compensation at Eli Lilly, including $1.50M salary, $3.62M bonus and $7.84M in stock. Most recently acquired 20,000 shares in Mar 2020. Currently holds stock worth $890.68M. Has donated $958.78M in stock to charitable causes. Led Eli Lilly as CEO for 8 years.
Compensation History
Annual executive compensation data for John C. Lechleiter, including salary, bonuses, and stock awards.
Year
2015
Total Compensation
$13.05M
Salary
$1.50M
Bonus
$3.62M
Other
$90.00K
Salary
$1.50MBoard Justification
The compensation philosophy is designed to attract and retain talented individuals while aligning executive compensation with company performance and shareholder interests.
Bonus
$3.62MBoard Justification
The annual cash bonus is based on company performance in three areas: revenue, EPS, and pipeline progress, with a maximum payout of 150% of the target based on performance metrics.
Other Compensation
$90.00KBoard Justification
This includes company matching contributions for the 401(k) plan and other benefits.
Restricted Stock
Board Justification
The stock awards that vested in 2015 were based on performance awards from previous years, specifically the 2014-2016 performance period, with a payout of 150% of target due to exceeding EPS growth targets.
Performance Metrics
The performance metrics for determining the CEO's compensation include revenue growth, earnings per share (EPS), and progress on the company's pipeline.
John C. Lechleiter
Ex-CEO of Eli Lilly
Education
Ph.D. in Organic Chemistry from Harvard University
Sector of Economy
Healthcare
Born
May 20, 1952 - 73 years ago
CEO of Eli Lilly for
8 years 8 months (Apr 2008 - Dec 2016)
Previous Experience
President and Chief Operating Officer of Eli Lilly & Co.
Holdings
Track John C. Lechleiter's stock holdings and portfolio value over time.
Total Stock Sold
$473.24K
$473.24K
5,406 NKE shares
What if they kept their stock?
If John C. Lechleiter didn't sell their stock, today they would have:
Extra NKE5,406 shares worth $355.12K.
This is -24.96% and $118.12K less than what they got when they sold the stock.
Charitable Transactions
945,087 shares
LLY
Recent Charitable Transactions
398,130 shares
LLY
May 4, 2017
Charity
34,319 shares
LLY
Dec 31, 2016
Charity
10,808 shares
LLY
Dec 31, 2015
Charity
12,955 shares
LLY
Nov 3, 2015
Charity
15,909 shares
LLY
Apr 28, 2015
Charity
4,245 shares
LLY
Dec 31, 2014
Charity
Insider Trading
John C. Lechleiter's recent stock transactions, purchases, and sales filed with the SEC.
$104.58K
F at $5.23/share
Mar 12, 2020
Purchase
$81.40K
F at $8.14/share
Feb 12, 2020
Purchase
$216.94K
F at $8.68/share
Oct 25, 2019
Purchase
$95.95K
F at $9.60/share
Jul 29, 2019
Purchase
$471.02K
NKE at $87.13/share
Jul 26, 2019
Sale
$103.20K
F at $10.32/share
May 10, 2019
Purchase
2,050 shares
NKE
Sep 20, 2018
Received
$98.89K
F at $9.89/share
Aug 2, 2018
Purchase
$55.86K
F at $11.17/share
May 11, 2018
Purchase
$51.39K
F at $10.28/share
Feb 9, 2018
Purchase
Rivals
Compare John C. Lechleiter with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M
Robert A. Bradway
CEO of Amgen
2024 Compensation
Stock
$0.00
Salary
$1.87M
Bonus
$0.00
Other
$714.33K
Total Holdings
$269.12M